Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock
Completed
Conditions studied: Sepsis
In brief
The purpose of this research study is to determine if a chemical marker in the blood, hypoxia-inducible factor (HIF-1 alpha), can be used to predict subject's hospital outcomes when the subject is diagnosed with sepsis. Sepsis is defined as either the presence of pathogenic organisms or their toxins in the blood and tissues. Sepsis is one of the most significant challenges in critical care medicine. The investigators propose that hypoxia-induced expression of HIF-1 alpha will correlate with the clinical features of Sepsis and in the future, HIF-1 alpha may be used as a biomarker in Sepsis.
Key facts
- Study ID
- NCT02163473
- Run by
- University of Florida
- People needed
- 63
- Starts
- 2013-01-01
- Expected to finish
- 2015-06-01
- Last updated by the study team
- 2016-10-13
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Florida — Gainesville, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.